AAPL316.85-2.85 (-0.89%) ▼|ABBV256.42+0.94 (+0.37%) ▲|ABT110.36-2.11 (-1.88%) ▼|ACN189.76+0.15 (+0.08%) ▲|ADBE292.79+1.27 (+0.44%) ▲|AMAT458.39-3.28 (-0.71%) ▼|AMD470.72+5.14 (+1.10%) ▲|AMGN429.88-2.54 (-0.59%) ▼|AMT175.70-0.53 (-0.30%) ▼|AMZN259.77-6.66 (-2.50%) ▼|AVGO370.34+1.55 (+0.42%) ▲|AXP330.17-3.03 (-0.91%) ▼|BA207.78-2.04 (-0.97%) ▼|BAC61.94-0.38 (-0.61%) ▼|BKNG199.09-6.54 (-3.18%) ▼|BLK1,155.61-8.87 (-0.76%) ▼|BMY66.81+0.23 (+0.35%) ▲|BNY161.28-1.22 (-0.75%) ▼|BRK-B504.03-0.97 (-0.19%) ▼|C131.62-1.28 (-0.96%) ▼|CAT797.47-2.78 (-0.35%) ▼|CL89.82-0.93 (-1.02%) ▼|CMCSA26.62-0.44 (-1.63%) ▼|COF214.51-1.16 (-0.54%) ▼|COP132.49+2.14 (+1.64%) ▲|COST943.89-1.58 (-0.17%) ▼|CRM257.54+1.54 (+0.60%) ▲|CSCO110.49+0.56 (+0.51%) ▲|CVS93.91+0.85 (+0.91%) ▲|CVX206.14+4.28 (+2.12%) ▲|DE654.91+24.58 (+3.90%) ▲|DHR213.56-2.51 (-1.16%) ▼|DIS107.55-0.55 (-0.51%) ▼|DUK119.91-0.34 (-0.28%) ▼|EMR152.44-2.74 (-1.77%) ▼|FDX327.40-3.48 (-1.05%) ▼|GD371.35-7.97 (-2.10%) ▼|GE335.71-6.87 (-2.01%) ▼|GEV898.53-13.40 (-1.47%) ▼|GILD146.34+0.66 (+0.45%) ▲|GM86.32+0.05 (+0.06%) ▲|GOOG335.41-7.47 (-2.18%) ▼|GOOGL339.35-7.24 (-2.09%) ▼|GS1,025.90-8.09 (-0.78%) ▼|HD327.83-2.36 (-0.71%) ▼|HON213.53-3.90 (-1.79%) ▼|IBM233.87-1.72 (-0.73%) ▼|INTC89.51+0.04 (+0.04%) ▲|INTU359.30+1.24 (+0.35%) ▲|ISRG376.86+4.26 (+1.14%) ▲|JNJ265.85-2.19 (-0.82%) ▼|JPM356.02-1.60 (-0.45%) ▼|KO88.67-0.99 (-1.10%) ▼|LIN489.58+0.07 (+0.01%) ▲|LLY1,156.73-17.88 (-1.52%) ▼|LMT561.23-2.62 (-0.46%) ▼|LOW204.70-3.35 (-1.61%) ▼|LRCX301.49-0.41 (-0.14%) ▼|MA589.31-5.99 (-1.01%) ▼|MCD263.54-1.46 (-0.55%) ▼|MDLZ62.07-0.29 (-0.47%) ▼|MDT90.65-0.58 (-0.64%) ▼|META572.34-5.68 (-0.98%) ▼|MMM171.83-2.51 (-1.44%) ▼|MO68.48-0.17 (-0.25%) ▼|MRK147.76-0.59 (-0.40%) ▼|MS213.32-1.45 (-0.68%) ▼|MSFT507.29-6.24 (-1.22%) ▼|MU958.73+25.87 (+2.77%) ▲|NEE82.34+0.50 (+0.61%) ▲|NFLX81.05-0.67 (-0.82%) ▼|NKE39.06-0.54 (-1.36%) ▼|NOW147.99+3.28 (+2.27%) ▲|NVDA220.78+3.23 (+1.48%) ▲|ORCL149.12-1.73 (-1.15%) ▼|PEP140.34-0.73 (-0.52%) ▼|PFE28.46+0.50 (+1.79%) ▲|PG145.12+1.34 (+0.93%) ▲|PLTR186.38+0.09 (+0.05%) ▲|PM187.30-4.59 (-2.39%) ▼|QCOM170.48+6.29 (+3.83%) ▲|RTX209.91+2.16 (+1.04%) ▲|SBUX106.01-0.25 (-0.23%) ▼|SCHW108.98-0.85 (-0.77%) ▼|SO88.70+0.71 (+0.81%) ▲|SPG213.51+1.15 (+0.54%) ▲|T26.19+0.30 (+1.16%) ▲|TMO617.10-5.08 (-0.82%) ▼|TMUS180.44-0.93 (-0.51%) ▼|TSLA367.95+19.20 (+5.51%) ▲|TXN255.19-5.72 (-2.19%) ▼|UBER75.04-0.60 (-0.79%) ▼|UNH394.24+4.87 (+1.25%) ▲|UNP301.37+0.60 (+0.20%) ▲|UPS103.79-0.47 (-0.45%) ▼|USB61.69+0.10 (+0.16%) ▲|V378.83-0.61 (-0.16%) ▼|VZ50.70+0.68 (+1.36%) ▲|WFC86.57+0.16 (+0.19%) ▲|WMT105.70+0.83 (+0.79%) ▲|XOM163.39+2.41 (+1.50%) ▲|AAPL316.85-2.85 (-0.89%) ▼|ABBV256.42+0.94 (+0.37%) ▲|ABT110.36-2.11 (-1.88%) ▼|ACN189.76+0.15 (+0.08%) ▲|ADBE292.79+1.27 (+0.44%) ▲|AMAT458.39-3.28 (-0.71%) ▼|AMD470.72+5.14 (+1.10%) ▲|AMGN429.88-2.54 (-0.59%) ▼|AMT175.70-0.53 (-0.30%) ▼|AMZN259.77-6.66 (-2.50%) ▼|AVGO370.34+1.55 (+0.42%) ▲|AXP330.17-3.03 (-0.91%) ▼|BA207.78-2.04 (-0.97%) ▼|BAC61.94-0.38 (-0.61%) ▼|BKNG199.09-6.54 (-3.18%) ▼|BLK1,155.61-8.87 (-0.76%) ▼|BMY66.81+0.23 (+0.35%) ▲|BNY161.28-1.22 (-0.75%) ▼|BRK-B504.03-0.97 (-0.19%) ▼|C131.62-1.28 (-0.96%) ▼|CAT797.47-2.78 (-0.35%) ▼|CL89.82-0.93 (-1.02%) ▼|CMCSA26.62-0.44 (-1.63%) ▼|COF214.51-1.16 (-0.54%) ▼|COP132.49+2.14 (+1.64%) ▲|COST943.89-1.58 (-0.17%) ▼|CRM257.54+1.54 (+0.60%) ▲|CSCO110.49+0.56 (+0.51%) ▲|CVS93.91+0.85 (+0.91%) ▲|CVX206.14+4.28 (+2.12%) ▲|DE654.91+24.58 (+3.90%) ▲|DHR213.56-2.51 (-1.16%) ▼|DIS107.55-0.55 (-0.51%) ▼|DUK119.91-0.34 (-0.28%) ▼|EMR152.44-2.74 (-1.77%) ▼|FDX327.40-3.48 (-1.05%) ▼|GD371.35-7.97 (-2.10%) ▼|GE335.71-6.87 (-2.01%) ▼|GEV898.53-13.40 (-1.47%) ▼|GILD146.34+0.66 (+0.45%) ▲|GM86.32+0.05 (+0.06%) ▲|GOOG335.41-7.47 (-2.18%) ▼|GOOGL339.35-7.24 (-2.09%) ▼|GS1,025.90-8.09 (-0.78%) ▼|HD327.83-2.36 (-0.71%) ▼|HON213.53-3.90 (-1.79%) ▼|IBM233.87-1.72 (-0.73%) ▼|INTC89.51+0.04 (+0.04%) ▲|INTU359.30+1.24 (+0.35%) ▲|ISRG376.86+4.26 (+1.14%) ▲|JNJ265.85-2.19 (-0.82%) ▼|JPM356.02-1.60 (-0.45%) ▼|KO88.67-0.99 (-1.10%) ▼|LIN489.58+0.07 (+0.01%) ▲|LLY1,156.73-17.88 (-1.52%) ▼|LMT561.23-2.62 (-0.46%) ▼|LOW204.70-3.35 (-1.61%) ▼|LRCX301.49-0.41 (-0.14%) ▼|MA589.31-5.99 (-1.01%) ▼|MCD263.54-1.46 (-0.55%) ▼|MDLZ62.07-0.29 (-0.47%) ▼|MDT90.65-0.58 (-0.64%) ▼|META572.34-5.68 (-0.98%) ▼|MMM171.83-2.51 (-1.44%) ▼|MO68.48-0.17 (-0.25%) ▼|MRK147.76-0.59 (-0.40%) ▼|MS213.32-1.45 (-0.68%) ▼|MSFT507.29-6.24 (-1.22%) ▼|MU958.73+25.87 (+2.77%) ▲|NEE82.34+0.50 (+0.61%) ▲|NFLX81.05-0.67 (-0.82%) ▼|NKE39.06-0.54 (-1.36%) ▼|NOW147.99+3.28 (+2.27%) ▲|NVDA220.78+3.23 (+1.48%) ▲|ORCL149.12-1.73 (-1.15%) ▼|PEP140.34-0.73 (-0.52%) ▼|PFE28.46+0.50 (+1.79%) ▲|PG145.12+1.34 (+0.93%) ▲|PLTR186.38+0.09 (+0.05%) ▲|PM187.30-4.59 (-2.39%) ▼|QCOM170.48+6.29 (+3.83%) ▲|RTX209.91+2.16 (+1.04%) ▲|SBUX106.01-0.25 (-0.23%) ▼|SCHW108.98-0.85 (-0.77%) ▼|SO88.70+0.71 (+0.81%) ▲|SPG213.51+1.15 (+0.54%) ▲|T26.19+0.30 (+1.16%) ▲|TMO617.10-5.08 (-0.82%) ▼|TMUS180.44-0.93 (-0.51%) ▼|TSLA367.95+19.20 (+5.51%) ▲|TXN255.19-5.72 (-2.19%) ▼|UBER75.04-0.60 (-0.79%) ▼|UNH394.24+4.87 (+1.25%) ▲|UNP301.37+0.60 (+0.20%) ▲|UPS103.79-0.47 (-0.45%) ▼|USB61.69+0.10 (+0.16%) ▲|V378.83-0.61 (-0.16%) ▼|VZ50.70+0.68 (+1.36%) ▲|WFC86.57+0.16 (+0.19%) ▲|WMT105.70+0.83 (+0.79%) ▲|XOM163.39+2.41 (+1.50%) ▲|
22.9 C
New York
Tuesday, September 1, 2026

Tag: market entry

newssourceFORcompanyinformationcontent1releasesmarket

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed the first tranche of its previously announced private placement offering (the “Offering”). The first tranche of the Offering consisted of the issuance of 2,900,000 units of the Company (each, a “Unit”), at a price of $0.021 per Unit, for total gross proceeds to Revive of $60,900. Furthermore, the Company announces that it has settled an amount of $67,400 owing pursuant to an arm’s length note through the issuance of 3,209,523 Units, at a price of $0.021 per Unit, being the same issue price and security offered pursuant to the Offering.

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

DAESHIN MC Expands Hungarian Clean Technology Partnership… Targeting the European Market Through a Joint German Exhibition

SEOUL, South Korea, Aug. 11, 2025 /PRNewswire/ -- South Korean environmental technology specialist DAESHIN MC has launched a comprehensive European market expansion by strengthening its...

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

Biomarkers Market to Grow at a CAGR of 12.3% from 2025 to 2032 | SkyQuest Technology Consulting

The Biomarkers Market is anticipated to expand at a rapid pace due to the increasing demand for personalized medicine, rising prevalence of chronic and...

Vitiligo Market to Register Incremental Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

The vitiligo market is witnessing steady growth due to rising disease awareness, improved diagnostic capabilities, and advancements in treatment options such as JAK inhibitors...

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight

The TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMarket entry

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers